Resverlogix Corporation Collaborates NexVas(TM) AD Program with Leading Alzheimer's Researcher at Sun Health Research Institute
CALGARY, ALBERTA--(MARKET WIRE)--Jun 19, 2007 -- Resverlogix Corp. ("Resverlogix") (Toronto:RVX.TO - News) is pleased to announce today that it has signed a collaborative research agreement with Dr. Larry Sparks of the Sun Health Research Institute (SHRI) to study Resverlogix's novel ApoA-I enhancing therapy for the treatment of Alzheimer's Disease (AD).